NCT07617038Enrolling by invitation
OE MRI to Predict Treatment Response After TACE in HCC Patients
Dynamic Oxygen-Enhanced (OE) MRI to Predict Treatment Response After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
To predict response of HCC to TACE using dynamic oxygen-enhanced (dOE)-MRI for assessment of the level of tumor hypoxia before and after treatment.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 16 Apr 2026
- Start date
- 27 Nov 2024
- Primary completion date
- 20 Dec 2027
- Lead sponsor
- Université de Montréal
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07617038
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 27 Nov 2024 to the primary completion date, 20 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- contraindication for MRI
- contraindication for contrast injection
- claustrophobia
Who the study is looking for
- no pulmonary disease
- able to stay 2 hours in MRI
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRCHUM Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.